Maria Kantzanou, Evangelos Kostares, Georgia Kostare, Evangelia Papagiannopoulou, Michael Kostares, Athanasios Tsakris
{"title":"Prevalence of Leishmaniasis among Blood Donors: A Systematic Review and Meta-Analysis.","authors":"Maria Kantzanou, Evangelos Kostares, Georgia Kostare, Evangelia Papagiannopoulou, Michael Kostares, Athanasios Tsakris","doi":"10.3390/diseases12070160","DOIUrl":null,"url":null,"abstract":"<p><p>Our study seeks to provide a comprehensive assessment of leishmaniasis prevalence among blood donors, employing rigorous methodologies to inform public health initiatives and transfusion safety measures. A thorough literature search was conducted using electronic databases (Medline, Scopus, Web of Science, and Google Scholar) to identify the relevant studies reporting the prevalence of leishmaniasis among blood donors, gathering a wide range of studies encompassing different geographic locations and time periods. The pooled prevalence with a 95% confidence interval (CI) was estimated, and quality assessment, outlier analysis, and influential analysis were performed to ensure the robustness and validity of the findings. Our search and subsequent analyses led to the inclusion of thirty-five studies in our review. Using molecular diagnostic methods, the prevalence was estimated at 2.3% (95% CI 1-3.9%), while serological diagnostic methods indicated a higher prevalence rate of 4.5% (95% CI 2.8-6.7%). Notably, we observed significant heterogeneity among the included studies for each analysis. The observed heterogeneity highlights the need for future research to delve into the factors influencing leishmaniasis prevalence, with prospective and retrospective studies addressing the limitations identified in this review.</p>","PeriodicalId":72832,"journal":{"name":"Diseases (Basel, Switzerland)","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11276524/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/diseases12070160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Our study seeks to provide a comprehensive assessment of leishmaniasis prevalence among blood donors, employing rigorous methodologies to inform public health initiatives and transfusion safety measures. A thorough literature search was conducted using electronic databases (Medline, Scopus, Web of Science, and Google Scholar) to identify the relevant studies reporting the prevalence of leishmaniasis among blood donors, gathering a wide range of studies encompassing different geographic locations and time periods. The pooled prevalence with a 95% confidence interval (CI) was estimated, and quality assessment, outlier analysis, and influential analysis were performed to ensure the robustness and validity of the findings. Our search and subsequent analyses led to the inclusion of thirty-five studies in our review. Using molecular diagnostic methods, the prevalence was estimated at 2.3% (95% CI 1-3.9%), while serological diagnostic methods indicated a higher prevalence rate of 4.5% (95% CI 2.8-6.7%). Notably, we observed significant heterogeneity among the included studies for each analysis. The observed heterogeneity highlights the need for future research to delve into the factors influencing leishmaniasis prevalence, with prospective and retrospective studies addressing the limitations identified in this review.
我们的研究旨在全面评估利什曼病在献血者中的流行情况,采用严格的方法为公共卫生倡议和输血安全措施提供信息。我们使用电子数据库(Medline、Scopus、Web of Science 和 Google Scholar)进行了全面的文献检索,以确定报告利什曼病在献血者中流行情况的相关研究,收集了涵盖不同地理位置和时间段的大量研究。我们估算了具有 95% 置信区间 (CI) 的汇总流行率,并进行了质量评估、离群值分析和影响分析,以确保研究结果的稳健性和有效性。通过搜索和后续分析,我们将 35 项研究纳入了综述。使用分子诊断方法,患病率估计为 2.3%(95% CI 1-3.9%),而血清诊断方法显示患病率更高,为 4.5%(95% CI 2.8-6.7%)。值得注意的是,我们在每项分析中都观察到了所纳入研究之间的显著异质性。观察到的异质性突出表明,今后的研究需要深入探讨影响利什曼病流行率的因素,并通过前瞻性和回顾性研究解决本综述中发现的局限性。